Ar gyfer hydref 2023, mae’r JCVI yn argymell:dylid defnyddio'r brechlyn deufalent Omicron BA4-5 mRNA ynghyd â’r brechlyn unfalent XBB cymeradwy, yn amodol ar drwyddedu gan yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA)dylai’r brechlynnau ar gyfer yr amrywiolion Covid-19 diweddaraf gael eu blaenoriaethu i’w defnyddio mewn unigolion a chanddynt risg glinigol unigol uwch o ddatblygu symptomau COVID-19 difrifol
For autumn 2023, the JCVI is recommending:the use of both the approved bivalent Omicron BA4-5 mRNA and monovalent XBB vaccines (subject to licensure by the Medicines and Healthcare products Regulatory Agency (MHRA))the latest Covid-19 variant vaccines which are available should be prioritised for use in persons at higher individual clinical risk of severe Covid-19.